The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Some Placebos More Effective Than Others in Osteoarthritis

Some Placebos More Effective Than Others in Osteoarthritis

July 28, 2015 • By Will Boggs, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters Health)—Some placebos are more effective than others, and these differences can influence the apparent outcomes of clinical trials, according to a systematic review and meta-analysis of osteoarthritis trials.

You Might Also Like
  • Don’t Rule Out Placebos for Osteoarthritis Pain Control
  • Diclofenac Patch, Piroxicam Most Effective Topical NSAIDs for Osteoarthritis
  • Placebos: Their Underappreciated Impact in Pharmaceutical Trials

“More surprising than the fact that all placebos are not equal is the magnitude of that difference,” Dr. Raveendhara R. Bannuru, from Tufts Medical Center, Boston, told Reuters Health by email. “In particular, we found that intra-articular placebo was more effective than the active drug Tylenol.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

In a recent study, Dr. Bannuru’s team found that conclusions regarding the effectiveness of various pharmacological treatments for knee osteoarthritis could differ based on how alternative placebos were treated within a network analysis model.

Their current investigation used a network meta-analysis to determine whether the different placebo interventions used in knee osteoarthritis trials differ in efficacy and to quantify the effect of differential placebo effects on active-treatment effect estimates.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Intra-articular placebo and topical placebo had significantly greater effects than oral placebo, with the effect size of oral placebo being comparable to that of acetaminophen.

The effect sizes increased with the increases in mean baseline pain scores, such that every 10-point increase over a mean of 50 points translated into a 1.5-point increase on a 0–100 scale, according to the July 28 Annals of Internal Medicine online report.

The choice of placebo significantly influenced the apparent relative effect sizes of active treatments. Depending on the placebo model used, for example, the ranking of oral nonselective nonsteroidal anti-inflammatory drugs could range from third to most effective.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

“Our results should be interpreted with care,” the researchers noted. “The purpose of this study was not to determine the presence versus absence of an absolute placebo effect but rather to determine the relative effects of different placebo interventions. This analysis enabled us to consider how these differences affect estimates of active treatment effects, as well as to better understand the embedded therapeutic benefit that placebo interventions may confer.”

“The take-home message for physicians and researchers is that placebos are not null in efficacy, nor are they equivalent to one another,” Dr. Bannuru said. “Physicians should consider the method of administration when choosing knee osteoarthritis treatments. For researchers, selection of appropriate placebo controls is an important consideration in the design of future clinical trials. Also, the comparative effectiveness of active treatments depends on the type of placebo it is being compared to.”

“Future research is needed to rule out potential confounders, such as differences in trial design or study populations, that could otherwise explain these differences among placebos,” Dr. Bannuru added. “Such endeavors could thereby confirm the potential clinical benefits associated with treatment administration methods.”

Pages: 1 2 | Single Page

Filed Under: Conditions, Drug Updates, Osteoarthritis Tagged With: Nonsteroidal anti-inflammatory drugs (NSAIDs), Osteoarthritis, placebo

You Might Also Like:
  • Don’t Rule Out Placebos for Osteoarthritis Pain Control
  • Diclofenac Patch, Piroxicam Most Effective Topical NSAIDs for Osteoarthritis
  • Placebos: Their Underappreciated Impact in Pharmaceutical Trials
  • Knee Injuries Associated with Accelerated Knee Osteoarthritis

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)